Krishnaswamy Yeleswaram, Chief Development Officer at Rapport Therapeutics, Inc. (RAPP), sold 20,225 shares at $39.99 ($809K) on 2026-04-17, disclosed to the SEC on 2026-04-21.
Scheduled sale ($809k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RAPP | SELL | 2026-04-14 | $696K | — | Filing → |
| RAPP | SELL | 2026-04-09 | $13K | — | Filing → |
| RAPP | SELL | 2026-03-26 | $607K | — | Filing → |